載入中
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.
前收盤價
US$9.77
−US$0.21 · -2.10%
盤前
US$9.71
−US$0.06 · -0.61%
10月8日 上午9:25 ET
盤中時間採用ET。市場資料可能有所延遲。
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.
日內區間
目前US$9.77
52週區間
目前US$9.77
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
15
估值過高
情緒
44
多空交錯
風險
56
風險偏高
動能
34
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.
日內區間
目前US$9.77
52週區間
目前US$9.77
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | 1572.8萬 USD | 484.4萬 USD | 570.8萬 USD |
| 銷貨成本 | — | 681.39萬 USD | — | — | 1039.1萬 USD |
| 毛利 | — | −681.39萬 USD | 1572.8萬 USD | 484.4萬 USD | −468.3萬 USD |
| 研究與開發 | 1.17億 USD | 8990.19萬 USD | 6022.3萬 USD | 7554.3萬 USD | 7033.6萬 USD |
| 銷售、一般及管理費用 | 3601萬 USD | 2381.09萬 USD | 3193.8萬 USD | 2593.2萬 USD | 2382.7萬 USD |
| 營業費用 | 1.47億 USD | 1.14億 USD | 9216萬 USD | 1.01億 USD | 9393.1萬 USD |
| 利息收入 | 60.1萬 USD | 272.6萬 USD | 371.4萬 USD | 42.7萬 USD | 52.1萬 USD |
| 利息支出 | — | — | — | — | 69萬 USD |
| 折舊和攤銷 | 319.4萬 USD | 681.39萬 USD | 1316.2萬 USD | 1316.2萬 USD | 837.6萬 USD |
| 營業利益 | −1.47億 USD | −1.21億 USD | −7643.2萬 USD | −9663.1萬 USD | −9861.4萬 USD |
| 淨利 | −1.47億 USD | −1.14億 USD | −7272.6萬 USD | −9627.4萬 USD | −9780.9萬 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
